kahalalide f

Kahalalide F is a **cyclic depsipeptide** originally isolated from the Hawaiian marine mollusk *Elysia rufescens* and the green alga *Bryopsis* sp. It is under development as an **antineoplastic agent** and has shown potent, **selective cytotoxic and cytostatic activity against solid tumor cell lines**, notably prostate, breast, colon, and non-small cell lung cancers, with reduced sensitivity in non-tumor cell lines. The **mechanism of action** is not fully elucidated but is associated with **disruption of the plasma membrane, induction of oncosis (a non-apoptotic cell death involving loss of membrane integrity), mitochondrial and lysosomal dysfunction in tumor cells**, and potentially depolarization of cell membranes and ATP depletion. It has progressed through Phase I and II clinical trials primarily for **advanced solid tumors**, including prostate cancer, non-small cell lung cancer, hepatocarcinoma, colorectal cancer, bladder cancer, and cholangiocarcinoma. Formulated for intravenous administration, it was developed primarily by PharmaMar.

Other names

149204-42-2BQD6E2ZXEABQD-6E2ZXEABQD 6E2ZXEAUNII-BQD6E2ZXEAUNII-BQD-6E2ZXEAUNII-BQD 6E2ZXEA